Tonix Pharmaceuticals Holding (TNXP) Change in Accured Expenses (2011 - 2026)

Tonix Pharmaceuticals Holding's Change in Accured Expenses history runs 16 years deep, the most recent figure standing at -$2.1 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 30.07% year-over-year to -$2.1 million in Q1 2026; TTM through Mar 2026 was $12.6 million, a 90328.57% increase from a year earlier, with the FY2025 full-year figure at $11.7 million, up 886.97% from the prior year.
• Change in Accured Expenses retreated to -$2.1 million in Q1 2026 per TNXP's latest filing, from $10.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $10.1 million in Q4 2025 and bottomed at -$3.0 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is $913000.0 (2024), against an average of $815470.6.
• Biggest YoY gain for Change in Accured Expenses was 581.98% in 2023; the steepest drop was 179.74% in 2023.
• Year by year, Change in Accured Expenses stood at $2.2 million in 2022, then soared by 100.54% to $4.4 million in 2023, then sank by 65.02% to $1.5 million in 2024, then surged by 551.29% to $10.1 million in 2025, then slumped by 120.46% to -$2.1 million in 2026.
• Per Business Quant, the three latest TNXP Change in Accured Expenses figures stand at -$2.1 million (Q1 2026), $10.1 million (Q4 2025), and $1.2 million (Q3 2025).